Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2021 Oct 4;11:19667. doi: 10.1038/s41598-021-99267-z

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

Sangyong Jung 1,#, Dong Ha Kim 2,#, Yun Jung Choi 2, Seon Ye Kim 2, Hyojeong Park 1, Hyeonjeong Lee 1, Chang-Min Choi 3, Young Hoon Sung 4, Jae Cheol Lee 5,✉, Jin Kyung Rho 4,✉
PMCID: PMC8490392  PMID: 34608255

Abstract

The emergence of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) with activating EGFR mutations is a major hindrance to treatment. We investigated the effects of p53 in primary sensitivity and acquired resistance to EGFR-TKIs in NSCLC cells. Changes in sensitivity to EGFR-TKIs were determined using p53 overexpression or knockdown in cells with activating EGFR mutations. We investigated EMT-related molecules, morphologic changes, and AXL induction to elucidate mechanisms of acquired resistance to EGFR-TKIs according to p53 status. Changes in p53 status affected primary sensitivity as well as acquired resistance to EGFR-TKIs according to cell type. Firstly, p53 silencing did not affect primary and acquired resistance to EGFR-TKIs in PC-9 cells, but it led to primary resistance to EGFR-TKIs through AXL induction in HCC827 cells. Secondly, p53 silencing in H1975 cells enhanced the sensitivity to osimertinib through the emergence of mesenchymal-to-epithelial transition, and the emergence of acquired resistance to osimertinib in p53 knockout cells was much slower than in H1975 cells. Furthermore, two cell lines (H1975 and H1975/p53KO) demonstrated the different mechanisms of acquired resistance to osimertinib. Lastly, the introduction of mutant p53-R273H induced the epithelial-to-mesenchymal transition and exerted resistance to EGFR-TKIs in cells with activating EGFR mutations. These findings indicate that p53 mutations can be associated with primary or acquired resistance to EGFR-TKIs. Thus, the status or mutations of p53 may be considered as routes to improving the therapeutic effects of EGFR-TKIs in NSCLC.

Subject terms: Cell biology, Molecular biology, Cancer, Cancer therapy, Targeted therapies

Introduction

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used as molecularly targeted drugs for non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations1–3. Although the emergence of acquired resistance to drugs is a growing problem, a variety of mechanisms of acquired resistance to EGFR-TKIs have been well defined. To date, several major mechanisms of acquired resistance have been reported, including secondary mutation of the EGFR gene4,5, amplification of the MET gene6, AXL activation7, and epithelial-to-mesenchymal transition (EMT)6,8, and effective pharmaceutical agents circumventing these mechanisms are being developed.

The p53 protein is one of the tumor suppressor genes that regulate the expression of various target genes involved in apoptosis, cell-cycle arrest, DNA repair, senescence, angiogenesis, and metastasis9. However, the p53 pathway is often mutated in cancer10, and mutations or deletions of the p53 gene are present in approximately 50% of all human cancers11. The status of p53 is an important factor influencing anti-cancer drug responses. Although responses differ depending on whether mutations cause a loss of wild-type p53 or a gain or loss of mutant p53, p53 mutations or deletions have been linked to drug resistance in acute lymphoblastic leukemia12, melanoma13, osteosarcoma14, and breast cancer15, as well as ovarian and testicular cancers16,17.

Mutations of p53 occur in about 30–40% of NSCLC patients and in patients with smoking-associated NSCLC18. NSCLC patients with mutant p53 generally have more aggressive disease, increased rates of resistance to chemotherapy, and shorter survival19,20. The association between p53 mutations and deletions with responsiveness to EGFR-TKIs has been confirmed by many studies21–26. There have been reports of decreased sensitivity to EGFR-TKIs among patients with concomitant EGFR and p53 mutations22,23,26. Our previous study showed that wild-type p53 is needed for gefitinib-induced apoptosis and leads to increased sensitivity to EGFR-TKIs through the enhancement of Fas/FasL-mediated signaling25. Moreover, Canale et al. reported that p53 mutations, especially exon-8 mutations, reduced responsiveness to EGFR-TKIs and worsen prognosis in EGFR-mutated NSCLC patients, mainly those harboring exon 19 deletions27. Although many studies have shown that p53 mutions are associated with resistance to EGFR-TKIs, the mechanisms underlying p53 mutation-mediated resistance to EGFR-TKIs are unclear. Additionally, it is unknown whether p53 mutations affect acquired resistance to EGFR-TKIs.

We investigated the role of p53 in NSCLC cells harboring mutant EGFR using p53 overexpression or knockout to determine sensitivity to EGFR-TKIs. We analyzed whether the loss of p53 or mutant p53 affects the sensitivity or acquired resistance to EGFR-TKIs.

Results

The effects of p53 on sensitivity to EGFR-TKIs in PC-9 cells

To evaluate the effects of p53 in primary sensitivity and acquired resistance to EGFR-TKIs in NSCLC cells with activating EGFR mutations, we generated p53 knockout cells, including PC-9 (EGFR-Del19, p53-R248Q), HCC827 (EGFR-Del19, p53-v218del), and H1975 (EGFR-L858R + T790M, p53-R273H), using CRISPR-Cas9 KO plasmids targeting the p53 gene. Firstly, p53 knockout in PC-9 cells did not lead to significant changes in the activity of EGFR-related signaling pathways, and it did not affect the sensitivity to gefitinib (Fig. 1a,b). Next, we established cells with acquired resistance to gefitinib using PC-9 and PC-9/p53KO cells (Fig. 1c). Two resistant cells (PC-9/GR and PC-9/p53KO/GR) exhibited acquired resistance to gefitinib during the same period (data not shown). To elucidate the mechanisms of acquired resistance to gefitinib, we first confirmed EGFR dependency. The treatment of EGFR shRNAs led to a reduction of EGFR expression and the inhibition of cell growth (Fig. 1d). However, we found that the activities of EGFR-related signaling pathways were maintained in the presence of gefitinib, unlike that observed in parental cells (Fig. 1e). We previously demonstrated that the emergence of T790M mutations was associated with acquired resistance to gefitinib or erlotinib in PC-9 cells28. Consistent with previous studies, T790M mutations were found in two resistant cells (Fig. 1f). Furthermore, these resistant cells were sensitive to osimertinib (Fig. 1g). These results demonstrate that the p53 status in PC-9 cells does not affect primary or acquired resistance to EGFR-TKIs.

Figure 1.

Figure 1

Open in a new tab

The effects of p53 on sensitivity to EGFR-TKIs in PC-9 cells. Endogenous p53 was silenced using a Crisper/Cas9 knockout system in PC-9 cells. (a) The indicated protein levels were analyzed by immunoblotting. (b,c) Two gefitinib-resistant cells (PC-9/GR and PC-9/p53KO/GR) were established as described in the Materials and Methods section. Cells were treated with the indicated doses of gefitinib for 72 h, and cell viability was determined using MTT assays. (d) Lentiviral constructs containing the negative control (NT) and EGFR shRNAs were introduced into the indicated cells, and EGFR suppression was confirmed by immunoblotting. Cell viability was measured by cell counting. (e) Cells were treated with the indicated doses of gefitinib for 6 h, and EGFR-related signaling proteins were analyzed by immunoblotting. (f) Cells were treated with the indicated doses of osimertinib for 72 h, and cell viability was determined using MTT assays. (g) EGFR mutations were measured by the PNAClamp™. ***p < 0.0005 compared with negative control shRNAs.

Silencing of p53 leads to primary resistance to EGFR-TKIs in HCC827 cells

Although p53 did not affect the sensitivity to EGFR-TKIs in PC-9 cells, p53 silencing in HCC827 cells led to a reduction of activity and expression of EGFR as well as resistance to EGFR-TKIs (Fig. 2a,b). Gefitinib treatment could effectively inhibit EGFR activation in HCC827 cells, but levels of phosphorylated EGFR and Akt were not decreased in HCC827/p53KO cells (Fig. 2c). To determine whether these resistant cells depend on EGFR signaling for growth, we suppressed the EGFR gene using two different EGFR-specific shRNAs, and suppression of the EGFR protein was confirmed by immunoblotting. The growth of the resistant cells (HCC827/p53KO) was independent of EGFR signaling (Fig. 2d). Interestingly, RNA-seq analysis revealed the induction of AXL and GAS6 in HCC827/p53KO that were associated with acquired resistance to EGFR-TKIs (data not shown)7,29. The induction of the activity and expression of AXL was confirmed using immunoblotting (Fig. 2e). To evaluate whether the induction of AXL was associated with acquired resistance to gefitinib in HCC827/p53KO cells, we used NPS-1034, an AXL inhibitor. The combination of gefitinib and NPS-1034 led to the restoration of sensitivity to gefitinib (Fig. 2f). These results demonstrate that the silencing of p53 could induce the primary resistance to EGFR-TKIs through the enhancement of AXL.

Figure 2.

Figure 2

Open in a new tab

The effects of p53 on sensitivity to EGFR-TKIs in HCC827 cells. Endogenous p53 was silenced using a Crisper/Cas9 knockout system in HCC827 cells. (a) The indicated protein levels were analyzed by immunoblotting. (b) Cells were treated with the indicated doses of gefitinib or osimertinib for 72 h, and cell viability was determined using MTT assays. (c) Cells were treated with the indicated doses of gefitinib for 6 h, and EGFR-related signaling proteins were analyzed by immunoblotting. (d) Lentiviral constructs containing the negative control (NT) and EGFR shRNAs were introduced into the indicated cells, and EGFR suppression was confirmed by immunoblotting. Cell viability was measured by cell counting. (e) Lysates were immunoprecipitated with an anti-AXL antibody and immunoblotted with the indicated antibodies. (f) HCC827/p53KO cells were treated with gefitinib, NPS-1034 or a combination of the two drugs for 72 h. The combined effects were measured using the MTT assay. ***p < 0.0005 compared with negative control shRNAs.

The p53 status affects primary or acquired resistance to osimertinib in H1975 cells

Likewise, the HCC827 results and the p53 silencing in H1975 cells led to reduced EGFR activity and expression (Fig. 3a). However, we observed morphologic differences between the H1975 and H1975/p53KO cells using a light microscope. H1975 cells were round and exhibited a loss of cell–cell contacts with a mesenchymal-like phenotype, whereas H1975/p53KO cells exhibited an epithelial phenotype with defined cell–cell contacts (Fig. 3b). Consistent with these morphological changes, epithelial marker proteins, including desmoplakin, EpCAM, and cytokeratin 8/18, were enhanced in H1975/p53KO cells, although there was no difference in E-cadherin expression between the two cell types (Fig. 3a). Interestingly, H1975/p53KO cells were more sensitive to osimertinib than H1975 cells (Fig. 3c,d). Consistent with these results, osimertinib treatment effectively inhibited EGFR-related signaling in H1975/p53KO cells compared with H1975 cells (Fig. 3e).

Figure 3.

Figure 3

Open in a new tab

The effects of p53 on sensitivity to EGFR-TKIs in H1975 cells. Endogenous p53 was silenced using a Crisper/Cas9 knockout system in H1975 cells. (a) The indicated protein levels were analyzed by immunoblotting. (b) Cells were evaluated for morphologic changes that were consistent with MET using a light microscope. (c,d) Cells were treated with the indicated doses of osimertinib for 72 h, and cell viability was determined using MTT assays and cell counting. (e) Cells were treated with the indicated doses of osimetinib for 6 h, and EGFR-related signaling proteins were analyzed by immunoblotting. (f) Two gefitinib-resistant cells (H1975/OR and H1975/p53KO/OR) were established as described in the Materials and Methods section. At 3 months after drug exposure, cells were treated with the indicated doses of osimertinib for 72 h, and cell viability was determined using MTT assays. ***p < 0.0005 compared with control.

To determine whether p53 affects acquired resistance to EGFR-TKIs, we established cells with acquired resistance to osimertinib using H1975 and H1975/p53KO cells. The period time of acquisition of resistance to osimertinib showed different patterns according to p53 status. H1975/OR cells were generated 3 months following exposure to osimertinib, whereas H1975/p53KO/OR cells took 6 months (Fig. 3f). Additionally, the mechanisms of acquired resistance to osimertinib in H1975/OR cells were the induction of EMT in previous studies30. However, changes in EMT were not observed in H1975/p53KO/OR cells (Supplementary Fig. S1). Taken together, these results showed that p53 could affect primary sensitivity as well as the mechanisms and time of acquired resistance to EGFR-TKIs.

Mutant p53-R273H induces EMT and leads to resistance to EGFR-TKIs

H1975 cells have mutant p53-R273H31,32. Some authors suggest that mutant p53-R273H gain of function induces EMT33,34. Thus, we investigated whether such mutant p53 affects the sensitivity to EGFR-TKIs via EMT induction in cells with activating EGFR mutations. When mutant p53-R273H was introduced into HCC827 and PC-9 cells, the induction of vimentin was observed in two cells (Fig. 4a). Although the changes of EMT-related molecules differed in the two cells, induction of the EMT-like phenotype was more evident in PC-9 cells than HCC827 via the reduction of E-cadherin, cytokeratin 8/18, EpCAM, and the induction of vimentin. EMT induction by mutant p53-R273H was also confirmed in other cells with wild-type or null p53 (Supplementary Fig. S2). Furthermore, the introduction of mutant p53-R273H led to resistance to EGFR-TKIs in two cells (Fig. 4b). Lastly, we examined migratory and invasive potential, which are considered functional hallmarks of EMT. We found that the ability to migrate and invade was significantly increased in cells that express mutant p53-R273H (Fig. 4c). Taken together, these findings suggest that the expression of mutant p53-R273H could lead to resistance to EGFR-TKIs via EMT induction.

Figure 4.

Figure 4

Open in a new tab

The effects of p53-R273H on sensitivity to EGFR-TKIs in NSCLC cells with activating EGFR mutations. Mutant p53-R273H was introduced into cells with activating EGFR mutations. (a) p53 and EMT-related protein levels were analyzed by immunoblotting. (b) Cells were treated with the indicated doses of gefitinib or osimertinib for 72 h, and cell viability was determined using MTT assays. (c) Cells were seeded onto either collagen- or Matrigel-coated polycarbonate filters to determine their migratory and invasive potentials, respectively. Cells were incubated in modified Boyden chambers for 24 h, and the cells that penetrated the filter were stained and counted using a light microscope. Experiments were conducted in triplicate. *p < 0.05; ***p < 0.0005 compared with control.

Discussion

Our previous study and other studies suggested that p53 is associated with primary and acquired resistance to EGFR-TKIs21–26. Recently, some studies have demonstrated that p53 mutations confer worse prognoses in EGFR-mutated NSCLC patients treated with EGFR-TKIs35–37. However, the mechanisms of primary and acquired resistance to EGFR-TKIs by mutant p53 are still unclear. To begin to address this issue, we investigated the role of mutant p53 in systems including overexpression or knockout of mutant p53. We used EGFR-mutated NSCLC cell lines, such as HCC827, PC-9, and H1975, with different types of p53 mutations. In previous studies, they were classified as PC-9 (p53-R248Q), HCC827 (p53-v218del), and H1975 (p53-R273H)38. Although the function of p53-v218del is unknown, p53-R248Q and p53-R273H were associated with cancer progression steps, including tumorigenesis, stemness, and metastasis, as gain-of-function mutant p5339–41. In our data, p53-R248Q did not affect the sensitivity and acquired resistance to EGFR-TKIs in PC-9 cells. However, the loss of p53-v218del led to primary resistance to EGFR-TKIs through AXL induction in HCC827 cells. Furthermore, p53-R273H expression directly led to EMT induction, and these phenomena were associated with primary and acquired resistance to EGFR-TKIs. Although the mechanisms of sensitivity and acquired resistance to EGFR-TKIs differed according to the type of p53 mutations, p53 mutations can affect sensitivity or acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells.

AXL receptor tyrosine kinase is known as a promising anti-cancer target42. In particular, some authors suggest that AXL is associated with acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC7,29. This resistance frequently accompanies EMT7. Although various studies have demonstrated the mechanisms of AXL-mediated drug resistance, the mechanisms underlying AXL upregulation are unclear. In our studies, the silencing of mutant p53-v218del led to AXL induction and subsequently resulted in resistance to EGFR-TKIs. Boysen et al. suggested that a loss of p53 function could induce AXL expression via downregulation of miR-34a in B-cell chronic lymphocytic leukemia43. Conversely, Vaughan et al. suggested that gain-of-function mutant p53 (R175H, R273H, and D281G) promotes AXL expression at both the RNA and protein level44. Thus, we are investigating the roles of p53 loss of function and gain of function to better understand AXL upregulation, although the roles can vary according to the type of mutant p53.

Accumulating evidence has revealed that EMT is correlated with a poor prognosis for NSCLC patients45,46 as well as acquired resistance to various chemotherapeutic agents, including EGFR-TKIs8,30,47–49. Some studies have demonstrated that TGF-β, IGF1R, AXL, Notch signaling, and miRNAs are involved in the EMT process7,50–52, although the mechanisms of EMT are complex and versatile. However, the mechanisms of EMT in acquired resistance to EGFR-TKIs are still unclear. In our study, we showed that mutant p53-R273H leads to the induction of an EMT-like phenotype. Furthermore, mutant p53-R273H played important roles in the emergence of acquired resistance to EGFR-TKIs. Cells with mutant p53-R273H appeared the induction of EMT as the mechanism of the acquired resistance to EGFR-TKIs, and the period of acquisition of resistance to EGFR-TKIs was shorter than for cells with mutant p53-R273HKO. Although the mechanisms of acquired resistance to EGFR-TKIs in cells with mutant p53-R273HKO were not known or revealed in this study, EMT induction was not observed. Thus, mutant p53-R273H can contribute to EMT-mediated resistance and short-term of EGFR-TKIs treatment.

A few limitations of this study should be taken into consideration. Firstly, many different types of tumors show a high incidence of p53 mutation, and there are many types of p53 mutations. Although some studies have suggested that p53 mutations, especially exon-8 mutations, reduce responsiveness to EGFR-TKIs and worsen the prognosis for patients with EGFR-mutated NSCLC27,35, further studies are needed to determine the potentially varying effects of the different p53 mutation types. Secondly, the detailed mechanisms underlying EMT induction by mutant p53-R273H were not investigated. Some studies have suggested that the inhibition of Twist1 degradation and miR-130b-ZEB1 pathways are associated with EMT and gain-of-function p53 mutations, including p53-R273H33,53. Thus, further research is required to identify the specific mechanisms of action involved.

In summary, mutant p53 can affect both primary and acquired resistance to EGFR-TKIs; in particular, mutant p53-R273H is associated with resistance to EGFR-TKIs via EMT induction. Thus, the p53 status should be a consideration in efforts to improve the therapeutic efficacy of EGFR-TKIs for NSCLC.

Methods

Cell culture and reagents

H1975 and HCC827 cell lines were obtained from the American Type Culture Collection (Rockville, MD), and the PC-9 cell line was provided by Dr. Kazuto Nishio (National Cancer Center Hospital, Tokyo, Japan). All cells were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) with 100 U/mL penicillin, 100 mg/mL streptomycin (Invitrogen), and 10% fetal bovine serum (FBS). Gefitinib, osimertinib, and NPS-1034 were purchased from Selleck Chemicals (Houston, TX, USA). We purchased 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution from Sigma (St. Louis, MO, USA).

Establishment of the p53-knockout EGFR mutant NSCLC cell lines

Cells were transfected with CRISPR-Cas9 Knockout (KO) plasmids with target-specific guide RNA (gRNA) of the p53 gene (LentiCRISPR v2, #52961, Addgene, Cambridge, MA, USA), which allows the insertion of the puromycin resistance gene. After 48 h, cells were selected at a concentration of 5 µg/mL puromycin, and p53 silencing was determined by immunoblotting.

Generation of cell lines with acquired resistance to EGFR-TKIs

All resistant cells were established by chronic, repeated exposure to gefitinib or osimertinib, as reported in previous studies28,30. For all experiments, resistant cells were cultured in a drug-free medium for at least 1 week to eliminate gefitinib or osimertinib. Gefitinib- and osimertinib-resistant cells are referred to as PC-9/GR and H1975/OR cells, respectively.

EGFR mutation analysis

A peptide nucleic acid (PNA)-mediated PCR clamping assay (PNACLamp EGFR Mutation Detection kit, PANAGENE Inc., Daejeon, Korea) was used to detect T790M mutations. The detection of T790M mutations was performed as previously described54.

Lentivirus-mediated gene suppression or overexpression

To suppress EGFR, we used shEGFR-1 (TRCN0000195303) and shEGFR-2 (TRCN0000298822). Cells were transiently infected with shControl, shEGFR-1, or shEGFR-2 for 48 h. After infection, EGFR expression was determined by immunoblotting. Cell viability was determined by trypan blue staining using an ADAM-MC automatic cell counter (NanoEnTek, Seoul, Korea). Exogenously expressed mutant p53-R273H, pLenti6/V5-p53-R273H (plasmid #22934), was purchased from Addgene (Cambridge, MA, USA). Cells were infected with viral particles for 48 h. After infection, cells were selected using 5 μg/mL blasticidin. Mutant p53 expression was determined by immunoblotting.

MTT assays

MTT assay was performed as previously described55. Briefly, cells (1 × 104) were seeded in 96-well plates overnight. The indicated drugs were added in a dose dependent manner and the cells were incubated for 72 h. The combined effects of drugs were assessed by MTT assay at a 1:1 ratio of each drug. CI values were determined by using the CalcuSyn Software (Biosoft). The results represent at least three independent experiments, and the error bars signify the standard deviation from the mean.

Invasion and migration assay

Cell migration and invasion assays were performed according to previously described method8. Triplicate results are expressed as mean (standard deviation).

Immunoblotting and immunoprecipitation

Whole-cell lysates were prepared as previously described55. Antibodies specific for p53 (1:2000, sc-126), p-EGFR (1:1000, Tyr1173, sc-101668), EGFR (1:2000, sc-373749), p-Erk (1:1000, Thr202/Tyr204, sc-16982), Erk (1:3000, sc-94), Akt (1:3000, sc-5298), AXL (1:1000, sc-1096), E-cadherin (1:1000, sc-71008), EpCAM (1:1000, sc-71059), desmoplakin (1:1000, sc-390975), cytokeratin-8/18 (1:1000, sc-70939) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); those for p-Akt (1:1000, Ser473, #4060), β-catenin (1:1000, #8480), p-AXL (1:1000, #4060), and vimentin (1:1000, #5741) were obtained from Cell Signaling Technology (Beverly, MA, USA). To assess the level of p-AXL, lysates were immunoprecipitated with an anti-AXL antibody and immunoblotted with an anti-phosphotyrosine (p-Tyr, 1:1000, sc-7020, Santa Cruz) antibody. The immunoblotting is representative of three independent experiments.

Statistical analyses

Data are presented as the mean ± standard deviation, and p values were determined using unpaired t-tests between groups with GraphPad Prism (GraphPad Software, San Diego, CA, USA).

Supplementary Information

Supplementary Information 1. (637KB, pdf)
Supplementary Information 2. (328.4KB, docx)

Acknowledgements

We thank the Laboratory of Animal Research core facilities at the ConveRgence mEDIcine Research Center (CREDIT), Asan Medical Center, for the use of their shared equipment, services, and expertise. This study was supported by a grant from the National Research Foundation of Korea (NRF), funding by the Korean government (2019R1A2C2006054 to J.K. Rho) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HR21C0198 to J.K. Rho).

Author contributions

S.J., J.C.L., and J.K.R. conceived and designed the study. S.J., D.H.K., Y.J.C., S.Y.K., H.P., H.L., and J.K.R. performed the experiments. S.J., D.H.K., Y.J.C., C.-M.C., Y.H.S., J.C.L., and J.K.R. analyzed the data. S.J., J.C.L., and J.K.R. wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

Data availability

All data generated or analyzed during this study are included in this published article and the Supplementary Information.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Sangyong Jung and Dong Ha Kim.

Contributor Information

Jae Cheol Lee, Email: jclee@amc.seoul.kr.

Jin Kyung Rho, Email: jkrho@amc.seoul.kr.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-021-99267-z.

References

  • 1.Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009;361:947–957. doi: 10.1056/NEJMoa0810699. [DOI] [PubMed] [Google Scholar]
  • 2.Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246. doi: 10.1016/S1470-2045(11)70393-X. [DOI] [PubMed] [Google Scholar]
  • 3.Yang JC, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–151. doi: 10.1016/S1470-2045(14)71173-8. [DOI] [PubMed] [Google Scholar]
  • 4.Kobayashi S, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005;352:786–792. doi: 10.1056/NEJMoa044238. [DOI] [PubMed] [Google Scholar]
  • 5.Pao W, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73. doi: 10.1371/journal.pmed.0020073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sequist LV, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011;3:75ra26. doi: 10.1126/scitranslmed.3002003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Zhang Z, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 2012;44:852–860. doi: 10.1038/ng.2330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Rho JK, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer. 2009;63:219–226. doi: 10.1016/j.lungcan.2008.05.017. [DOI] [PubMed] [Google Scholar]
  • 9.Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  • 10.Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer. 2004;91:1415–1419. doi: 10.1038/sj.bjc.6602164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wang W, Hu Y. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy. Med. Res. Rev. 2012;32:1159–1196. doi: 10.1002/med.20236. [DOI] [PubMed] [Google Scholar]
  • 12.Lam V, et al. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk. Res. 1999;23:871–880. doi: 10.1016/s0145-2126(99)00102-2. [DOI] [PubMed] [Google Scholar]
  • 13.Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res. 1998;8:17–23. doi: 10.1097/00008390-199802000-00004. [DOI] [PubMed] [Google Scholar]
  • 14.Asada N, Tsuchiya H, Tomita KD. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line. Anticancer Res. 1999;19:5131–5137. [PubMed] [Google Scholar]
  • 15.Berns EM, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 2000;60:2155–2162. [PubMed] [Google Scholar]
  • 16.Houldsworth J, et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene. 1998;16:2345–2349. doi: 10.1038/sj.onc.1201770. [DOI] [PubMed] [Google Scholar]
  • 17.Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: Spontaneously mutant selection. Cell Growth Differ. 1999;10:473–478. [PubMed] [Google Scholar]
  • 18.Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. J. Biomed. Biotechnol. 2011;2011:583929. doi: 10.1155/2011/583929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Custodio AB, et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J. Thorac. Oncol. 2009;4:891–910. doi: 10.1097/JTO.0b013e3181a4b8fb. [DOI] [PubMed] [Google Scholar]
  • 20.Tsao MS, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J. Clin. Oncol. 2007;25:5240–5247. doi: 10.1200/JCO.2007.12.6953. [DOI] [PubMed] [Google Scholar]
  • 21.Chang GC, et al. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem. Pharmacol. 2004;68:1453–1464. doi: 10.1016/j.bcp.2004.06.006. [DOI] [PubMed] [Google Scholar]
  • 22.Labbe C, et al. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC) Lung Cancer. 2017;111:23–29. doi: 10.1016/j.lungcan.2017.06.014. [DOI] [PubMed] [Google Scholar]
  • 23.Molina-Vila MA, et al. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2014;20:4647–4659. doi: 10.1158/1078-0432.CCR-13-2391. [DOI] [PubMed] [Google Scholar]
  • 24.Munsch D, et al. Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J. Biol. Chem. 2000;275:3867–3872. doi: 10.1074/jbc.275.6.3867. [DOI] [PubMed] [Google Scholar]
  • 25.Rho JK, et al. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res. 2007;67:1163–1169. doi: 10.1158/0008-5472.CAN-06-2037. [DOI] [PubMed] [Google Scholar]
  • 26.VanderLaan PA, et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017;106:17–21. doi: 10.1016/j.lungcan.2017.01.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Canale M, et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin. Cancer Res. 2017;23:2195–2202. doi: 10.1158/1078-0432.CCR-16-0966. [DOI] [PubMed] [Google Scholar]
  • 28.Rho JK, et al. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol. Cancer Res. 2009;7:1736–1743. doi: 10.1158/1541-7786.MCR-08-0504. [DOI] [PubMed] [Google Scholar]
  • 29.Taniguchi H, et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat. Commun. 2019;10:259. doi: 10.1038/s41467-018-08074-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Ji W, et al. Efficacy of the CDK7 inhibitor on EMT-associated resistance to 3rd generation EGFR-TKIs in non-small cell lung cancer cell lines. Cells. 2020 doi: 10.3390/cells9122596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Sun S, et al. Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis. Cell Death Dis. 2020;11:595. doi: 10.1038/s41419-020-02814-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Vaughan CA, et al. Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter. Oncotarget. 2016;7:12426–12446. doi: 10.18632/oncotarget.6998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Dong P, et al. Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene. 2013;32:3286–3295. doi: 10.1038/onc.2012.334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wang W, et al. Cathepsin L activated by mutant p53 and Egr-1 promotes ionizing radiation-induced EMT in human NSCLC. J. Exp. Clin. Cancer Res. 2019;38:61. doi: 10.1186/s13046-019-1054-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Canale M, et al. Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs. J. Clin. Med. 2020 doi: 10.3390/jcm9041047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Hou H, et al. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer Manag. Res. 2019;11:5665–5675. doi: 10.2147/CMAR.S201513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Qin K, Hou H, Liang Y, Zhang X. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: A meta-analysis. BMC Cancer. 2020;20:328. doi: 10.1186/s12885-020-06805-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Chou CW, et al. Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis. Sci. Rep. 2019;9:20403. doi: 10.1038/s41598-019-56532-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V. p53: The barrier to cancer stem cell formation. FEBS Lett. 2014;588:2580–2589. doi: 10.1016/j.febslet.2014.02.011. [DOI] [PubMed] [Google Scholar]
  • 40.Muller PA, Vousden KH. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 2014;25:304–317. doi: 10.1016/j.ccr.2014.01.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Olszewski MB, Pruszko M, Snaar-Jagalska E, Zylicz A, Zylicz M. Diverse and cancer typespecific roles of the p53 R248Q gainoffunction mutation in cancer migration and invasiveness. Int. J. Oncol. 2019;54:1168–1182. doi: 10.3892/ijo.2019.4723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Rankin EB, Giaccia AJ. The receptor tyrosine kinase AXL in cancer progression. Cancers (Basel). 2016 doi: 10.3390/cancers8110103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Boysen J, et al. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: Implications for therapy in p53-defective CLL patients. Leukemia. 2014;28:451–455. doi: 10.1038/leu.2013.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Vaughan CA, et al. Gain-of-function activity of mutant p53 in lung cancer through up-regulation of receptor protein tyrosine kinase Axl. Genes Cancer. 2012;3:491–502. doi: 10.1177/1947601912462719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Bremnes RM, et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J. Clin. Oncol. 2002;20:2417–2428. doi: 10.1200/JCO.2002.08.159. [DOI] [PubMed] [Google Scholar]
  • 46.Deeb G, et al. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: A study utilizing high-density tissue microarray and immunohistochemistry. Mod. Pathol. 2004;17:430–439. doi: 10.1038/modpathol.3800041. [DOI] [PubMed] [Google Scholar]
  • 47.Fischer KR, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527:472–476. doi: 10.1038/nature15748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer. 2013;13:714–726. doi: 10.1038/nrc3599. [DOI] [PubMed] [Google Scholar]
  • 49.Zheng X, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527:525–530. doi: 10.1038/nature16064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Arasada RR, Amann JM, Rahman MA, Huppert SS, Carbone DP. EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. Cancer Res. 2014;74:5572–5584. doi: 10.1158/0008-5472.CAN-13-3724. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Nurwidya F, et al. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial–mesenchymal transition in non-small cell lung cancer. Biochem. Biophys. Res. Commun. 2014;455:332–338. doi: 10.1016/j.bbrc.2014.11.014. [DOI] [PubMed] [Google Scholar]
  • 52.Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19:156–172. doi: 10.1038/cr.2009.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Yang-Hartwich Y, et al. p53-Pirh2 complex promotes Twist1 degradation and inhibits EMT. Mol. Cancer Res. 2019;17:153–164. doi: 10.1158/1541-7786.MCR-18-0238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Lee Y, et al. Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer. Thorac. Cancer. 2018;9:1104–1110. doi: 10.1111/1759-7714.12793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Rho JK, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 2014;74:253–262. doi: 10.1158/0008-5472.CAN-13-1103. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information 1. (637KB, pdf)
Supplementary Information 2. (328.4KB, docx)

Data Availability Statement

All data generated or analyzed during this study are included in this published article and the Supplementary Information.

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES